Bellicum halts trials after serious adverse event, looks for 'strategic alternatives'
2023-03-15
细胞疗法临床结果临床研究免疫疗法
Bellicum Pharmaceuticals is halting the Phase I/II trials for the only two candidates in its pipeline after reporting a serious adverse event — and is now evaluating “strategic alternatives” for the company after a rocky few years.
The company announced Tuesday
that the ongoing trials for its two GoCAR-T cell candidates in combination with rimiducid in pre-treated cancer patients,
BPX-601 and BPX-603
, are coming to a halt. This comes after a patient on BPX-601 experienced serious side effects, including grade 4 cytokine release syndrome. This was the second dose-limiting toxicity in the dose-escalation cohort.
Bellicum
$BLCM
shares dropped roughly 40% in pre-market trading Wednesday.
The BPX-601 trial was studying the safety and preliminary efficacy of the candidate in patients with metastatic castration-resistant prostate cancer. BPX-603 targeted HER2-positive solid tumorsHER2-positive solid tumors.
“While clinically meaningful efficacy has been observed — including 5 of 9 mCRPC patients treated achieving PSA50 response, 4 of whom achieved PSA90 response — the Company believes it does not have the necessary resources to optimize either the clinical dose and schedule of BPX-601 cells and the activating agent rimiducid, or the design of the BPX-601 cell construct to achieve a favorable risk/benefit profile,” the press release reads.
There seemed to be hope in February when president and CEO Rick Fair
said
there were “encouraging” early data from BPX-601. The company also reported other adverse events at the time, however, such as myelosuppression, grade 3 cytokine release syndrome and grade 4 immune effector cell neurotoxicity syndrome.
It’s been a long road for Bellicum, which
laid off
79% of its staff in 2020 after it reported disappointing results for BPX-601 in pancreatic cancer. It also stopped discovery research and new product development that year. At the time, the company said it would focus on BPX-601, BPX-603 and a third candidate that’s no longer in development.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。